Financial Performance - Revenue for the reporting period was RMB 224.51 million, a decrease of 2.99% compared to the same period last year[26] - Net profit attributable to shareholders of the listed company was RMB 109.84 million, an increase of 5.53% year-on-year[26] - Net cash flow from operating activities was RMB 89.21 million, a decrease of 18.30% compared to the same period last year[26] - Total assets at the end of the reporting period were RMB 954.86 million, a decrease of 3.25% compared to the end of the previous year[26] - Revenue for the first half of 2023 was RMB 224.51 million, a decrease of 3.0% compared to RMB 231.44 million in the same period last year[159] - Net profit for the first half of 2023 was RMB 109.88 million, an increase of 5.5% compared to RMB 104.11 million in the same period last year[160] - R&D expenses increased by 36.2% to RMB 22.43 million in the first half of 2023, up from RMB 16.46 million in the same period last year[159] - Operating cash flow for the first half of 2023 was RMB 89.21 million, a decrease of 18.3% compared to RMB 109.18 million in the same period last year[163] - Investment cash flow for the first half of 2023 was RMB 63.09 million, a significant improvement from a negative RMB 13.81 million in the same period last year[164] - Cash and cash equivalents at the end of the first half of 2023 were RMB 101.34 million, a slight decrease of 1.1% compared to RMB 102.42 million at the end of the same period last year[164] - Basic earnings per share for the first half of 2023 were RMB 0.61, an increase of 5.2% compared to RMB 0.58 in the same period last year[157] - Total comprehensive income for the first half of 2023 was RMB 109.84 million, an increase of 5.5% compared to RMB 104.08 million in the same period last year[157] - Sales expenses decreased by 11.5% to RMB 53.32 million in the first half of 2023, down from RMB 60.22 million in the same period last year[159] - The company paid dividends of RMB 108.00 million in the first half of 2023, an increase of 2.3% compared to RMB 105.60 million in the same period last year[164] - Operating cash flow decreased to 8.924 billion yuan in the first half of 2023 from 10.916 billion yuan in the same period last year[165] - Sales revenue from goods and services dropped to 21.537 billion yuan in H1 2023 compared to 22.693 billion yuan in H1 2022[165] - Investment cash inflow decreased to 64.039 billion yuan in H1 2023 from 77.161 billion yuan in H1 2022[165] - Cash outflow for investment activities reduced to 57.731 billion yuan in H1 2023 from 78.542 billion yuan in H1 2022[165] - Net cash flow from investment activities turned positive at 6.309 billion yuan in H1 2023, compared to -1.381 billion yuan in H1 2022[165] - Dividend payments increased to 108 million yuan in H1 2023 from 105.6 million yuan in H1 2022[166] - Net cash flow from financing activities was -108 million yuan in H1 2023, slightly lower than -105.6 million yuan in H1 2022[166] - Total comprehensive income for the period reached 109.841 million yuan[167] - Cash and cash equivalents increased by 443.293 million yuan in H1 2023, compared to a decrease of 102.49 million yuan in H1 2022[166] - Ending cash and cash equivalents balance stood at 993.23 million yuan as of H1 2023[166] - Total comprehensive income for the period reached RMB 104.08 million[171] - Net profit attributable to owners of the parent company was RMB 105.42 million[172] - Total equity at the end of the period amounted to RMB 783.93 million[173] - Capital reserve increased by RMB 60 million due to capital surplus transfer[172] - Undistributed profit decreased by RMB 1.33 million[171] - Total equity at the beginning of the period was RMB 866.83 million[174] - Comprehensive income for the period was RMB 109.88 million[174] - Profit distribution to owners amounted to RMB 108 million[174] - Total equity at the end of the period was RMB 783.93 million[173] - Capital reserve increased by RMB 60 million due to capital surplus transfer[172] - Total comprehensive income for the period reached RMB 104,109,471.31[178] - Capital reserve transferred to capital (or share capital) amounted to RMB 60,000,000.00[178] - Total owner's equity at the end of the period was RMB 785,449,422.44[179] Product Performance and Market Position - The company's main products, oral repair membrane and absorbable dura (spinal) membrane patch, have experienced rapid growth in recent years and are the primary sources of revenue[3] - The absorbable dura (spinal) membrane patch has been selected in the volume-based procurement in 6 provinces including Jiangsu, Shandong, Fujian, Henan, Hebei, and Anhui, but future expansion of volume-based procurement may impact the company's performance[3] - The company's absorbable dura mater patch successfully entered the provincial alliance centralized procurement in Liaoning Province and continued to win bids in Jiangsu Province[37] - The company's active biological bone product is within the scope of orthopedic medical consumables for centralized procurement in Sichuan, Shanxi, and Beijing[38] - The company's oral repair membrane and bone repair materials are expected to benefit from the reduction in dental implant costs and increased market demand[38] - Revenue from oral repair membrane products was 106.05 million yuan, a year-on-year decrease of 3.57%[45] - Revenue from absorbable dura mater patch products was 90.93 million yuan, a year-on-year increase of 6.13%[45] - The company's products are listed in 31 provinces, with over 2,600 product listings, an increase of about 270 compared to the end of 2022[46] - The company organized approximately 650 academic events to promote its products and enhance brand influence[46] - Calcium-silicon bioceramic bone repair material completed national enrollment for clinical trials[50] - Breast patch and uterine cavity repair film are in the clinical enrollment stage[50] - The company's product "HaiAo® Oral Repair Membrane" was selected for the "Shandong Manufacturing•Qilu Fine Products" list[44] - The company was awarded the title of "Yantai Green Factory"[44] - Cumulative completion of various product storage reached 448,200 pieces/bottles, a year-on-year increase of 7.79%[51] - The company completed the transfer verification for the hard brain (spinal) membrane patch, with the active biological bone expected to complete verification within the year and officially launch sales next year[51] - The company's main products, oral repair membrane and absorbable dura mater (spinal) patch, have achieved rapid growth in recent years, contributing significantly to the company's revenue[82] - The absorbable dura mater (spinal) patch has been selected in 6 provinces (Jiangsu, Shandong, Fujian, Henan, Hebei, Anhui) for volume-based procurement by the end of 2022, without significant pressure on performance growth[82] - The company is actively developing new products such as active biological bone, second-generation dura mater (spinal) patch, and uterine repair membrane, with active biological bone already obtaining registration certification[85] - The company faces risks related to the concentration of its main products, as any significant changes in market environment, downstream demand, or competition could impact performance[85] - High-value medical consumables, including the company's products, are increasingly subject to volume-based procurement policies, which may affect market competitiveness[86] - The company's products are implantable medical devices, and any quality issues could impact safety and effectiveness, potentially affecting production and operations[87] - The company relies on animal tissue as a key raw material, and any large-scale control of animal tissue nationwide could impact production and sales[87] - The company has established a comprehensive intellectual property protection system but still faces risks of core technology leakage or infringement[88] Research and Development - The company faces risks related to the research, development, and registration of new products, particularly for Class III medical devices, which require significant investment and have long development cycles[5] - R&D investment increased significantly by 36.26% to 22.43 million yuan due to more projects entering the clinical stage[62] - The company established a "Bioregenerative Materials Shandong Engineering Research Center" in collaboration with Donghua University, which was included in the new sequence management list by the Shandong Development and Reform Commission[55] - The company has established stable cooperative relationships with renowned domestic research institutions such as the Chinese Academy of Sciences and Sichuan University[59] Corporate Governance and Leadership - The company does not plan to distribute cash dividends, issue bonus shares, or convert capital reserve into share capital[6] - The company's registered address and other contact information remained unchanged during the reporting period[22] - The company's semi-annual report is disclosed on the Shenzhen Stock Exchange and major financial media, with the report available at the company's board office[23] - The company held multiple investor meetings and conference calls from May to June 2023, engaging with various institutional investors and funds to discuss business operations and development plans[90] - The 2023 First Extraordinary General Meeting had a 46.45% investor participation rate, and the 2022 Annual General Meeting had a 46.10% participation rate[93] - Key personnel changes included the resignation of Chairman Wang Tao on April 12, 2023, and the election of Song Kan as the new Chairman on April 13, 2023[94] - The company reported no profit distribution or capital reserve conversion to share capital for the first half of 2023[95] - No equity incentive plans, employee stock ownership plans, or other employee incentive measures were implemented during the reporting period[96] - The company maintains a comprehensive governance structure, ensuring compliance with laws and regulations, and timely, accurate, and complete information disclosure to investors[101] - The company actively communicates with investors through various channels, including a dedicated investor hotline, email, and the "Interactive Easy" platform, and participates in investor open days and protection awareness activities[102] - The company's actual controller, shareholders, and related parties have fulfilled their commitments during the reporting period, with no overdue commitments[110] - No non-operational fund occupation by controlling shareholders or other related parties occurred during the reporting period[112] - No illegal external guarantees were made during the reporting period[113] - The semi-annual financial report was not audited[114] - No major litigation or arbitration matters occurred during the reporting period[117] - No significant related transactions related to daily operations occurred during the reporting period[117] - No asset or equity acquisition or sale-related transactions occurred during the reporting period[118] - No significant contracts related to daily operations were reported during the reporting period[128] - The company announced the resignation of its chairman and changes in leadership positions in April 2023[129] - The total number of shares remains unchanged at 180,000,000, with 100% being unrestricted shares[133] - The largest shareholder, Mi Bohai, holds 33.87% of the shares, totaling 60,961,500 shares, with 16,000,000 shares pledged[135] - Longwood Biotechnologies Inc., a foreign legal entity, holds 7.67% of the shares, totaling 13,811,874 shares, with a decrease of 680,000 shares during the reporting period[135] - Sun Zongbing, an individual shareholder, holds 2.10% of the shares, totaling 3,784,763 shares, with no changes during the reporting period[135] - Jiaxing Zhenghai Venture Capital Partnership holds 2.10% of the shares, totaling 3,775,000 shares, with a decrease of 200,000 shares during the reporting period[135] - China Life Insurance Co., Ltd. holds 1.60% of the shares, totaling 2,884,200 shares, with no changes during the reporting period[135] Environmental and Social Responsibility - The company emphasized environmental protection, with all construction projects passing local environmental protection department inspections and emissions far below standards[98] - Wastewater and exhaust gas emissions were strictly managed, with quarterly third-party testing conducted to ensure compliance with environmental regulations[99] - The company highlighted its commitment to social responsibility, focusing on creating value, customer satisfaction, public welfare, and employee well-being since its establishment in 2003[99] - The company prioritizes product quality and safety, implementing a comprehensive quality management system from procurement to post-market surveillance, ensuring consumer protection[104] - The company adheres to environmental protection regulations, optimizing production processes and installing advanced environmental protection equipment to reduce waste emissions[105] - The company conducts quarterly third-party environmental testing and reports to the environmental protection bureau, with no environmental violations or penalties during the reporting period[106] - The company actively participates in social welfare activities, including supporting underprivileged students, donating winter clothing, and contributing to educational resources in remote areas[107] Financial Statements and Accounting Policies - The company's financial statements are prepared under the assumption of continued operation, with no significant factors affecting its ability to continue operations[185] - The company's financial statements comply with the latest Chinese Accounting Standards, accurately reflecting the company's financial status, operating results, and cash flows[187] - The company's fiscal year runs from January 1 to December 31[188] - The company's business operating cycle is short, with assets and liabilities classified based on a 12-month liquidity standard[189] - The company uses RMB as its functional currency[190] - For business combinations under common control, the company measures assets and liabilities at the book value of the acquired entity on the merger date[191] - For business combinations not under common control, the company recognizes goodwill if the merger cost exceeds the fair value of the acquired entity's identifiable net assets[192] - The company treats multiple transactions as a single transaction if they are economically linked or collectively achieve a complete business outcome[193] - When control of a subsidiary is lost, the company re-measures the remaining equity at fair value and recognizes any difference as investment income[195] - The company prepares consolidated financial statements based on the financial statements of the parent company and its subsidiaries[197] - The company determines its consolidation scope based on control, including all subsidiaries and controlled investees[198] Employee and Training - The company has 346 employees and conducted over 200 training sessions (including online) by the end of the reporting period[54] - The company has established a robust employee benefits system, including paid annual leave, heating subsidies, health check-ups, and more, while also enhancing employee training and development programs[103] Intellectual Property and Quality Management - The company holds 67 authorized patents and 95 registered trademarks as of June 30, 2023[58] - The company's products maintain a 100% pass rate upon leaving the factory[52] - The company was awarded the "Technical Demonstration Unit for the Implementation and Application of Unique Device Identification (UDI)" in January 2023[52] - The company has passed ISO 13485 and ISO 9001 quality management system certifications[60] Market Trends and Industry Outlook - The global medical device market is projected to grow at an annual rate of 5.6% from 2017 to 2024, reaching USD 594.5 billion by 2024[35] - China's medical device industry revenue reached approximately RMB 1.02 trillion in 2021, a year-on-year increase of 17%[36] Subsidiaries and Operations - The company's subsidiaries include Suzhou Zhenghai Biotechnology Co., Ltd. and Shanghai Kunyu Biotechnology Co., Ltd., both included in the consolidated financial statements[183] - The company operates in the medical device manufacturing sector, specifically in "6846 Implant Materials and Artificial Organs" and "6863 Dental Materials"[181] - The company's registered capital is RMB 180,000,000.00[181]

证券代码：300653 证券简称：正海生物 烟台正海生物科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |--------------------|---------------|-------------|---------------| | | | | 编号：2023007 | | | √特定对象调研 | □媒体采访 □ | 分析师会议 | | 投资者关系活动类别 | □新闻发布会 □ | 业绩说明会 | □路演活动 | √现场参观 □其他 参与单位名 称及人员 姓名 西部证券 陆伏葳；新华资产 张滢潭、杨帅、李浩、陈嘉桦、陈振 华；兴业证券 汪文博；民生加银 尹涛、郝梦娇、王泳鑫 时 间 2023 年 6 月 30 日 地 点 公司会议室+腾讯会议 上市公司接 待人员姓名 董事长、总经理宋侃先生 投资者关系活动主要内容 本次活动主要采用解答提问的方式进行，主要内容如下： 1、种植牙市场上半年整体恢复情况如何？ 答：以口腔种植牙相关产品的销售情况来看，今年 1、2 月份受到疫情放开、春 节假期的双重影响，销量同比大幅受挫，3 月份受部分民营口腔医院提前执行集采 ...

证券代码：300653 证券简称：正海生物 烟台正海生物科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |--------------------|---------------|-------------|---------------| | | | | 编号：2023006 | | | √特定对象调研 | □媒体采访 □ | 分析师会议 | | 投资者关系活动类别 | □新闻发布会 □ | 业绩说明会 | □路演活动 | √现场参观 □其他 深圳证券交易所 刘然、杨乔君；证券时报 黄翔；中泰证券 韩卓君、 参与单位名 称及人员 姓名 林琛；安信证券 董正、盖飞飞；投资者 李海霞、宋自磊、赵东华、 迟洪鹏等 26 人 时 间 2023 年 6 月 29 日 地 点 公司会议室 上市公司接 待人员姓名 董事长、总经理宋侃先生 投资者关系活动主要内容 一、公司介绍经营情况 正海生物成立于 2003 年，于 2017 年 5 月 16 日在深交所创业板上市，公司立足 再生医学领域，是一家致力于生物再生材料的研发、生产及销售为一体的高新技术 企业。目前已上市产品有口腔修复 ...

证券代码：300653 证券简称：正海生物 | --- | --- | --- | --- | |--------------------|---------------|-------------|---------------| | | | | 编号：2023005 | | | √特定对象调研 | □媒体采访 □ | 分析师会议 | | 投资者关系活动类别 | □新闻发布会 □ | 业绩说明会 | □路演活动 | √现场参观 □其他 参与单位名 称及人员 姓名 博时基金 柴文超；天风证券 张雪；华能信托 田维锋；冲积资产 任 毅；汇森投资 庞雨东；中隐基金 王进 唐臻宁 时 间 2023 年 6 月 5 日 地 点 公司会议室 上市公司接 待人员姓名 董事长、总经理宋侃先生 烟台正海生物科技股份有限公司 投资者关系活动记录表 投资者关系活动主要内容 本次活动主要采用解答提问的方式进行，主要内容如下： 1、种植牙市场的恢复情况如何？ 答：以口腔种植牙相关产品的销售情况来看，今年 1、2 月份受到疫情放开、春 节假期的双重影响，销量同比大幅受挫，3 月份受部分民营口腔医院提前执行集采 后价格的影响，公司产品销 ...

证券代码：300653 证券简称：正海生物 烟台正海生物科技股份有限公司 投资者关系活动记录表 编号：2023004 | --- | --- | --- | |--------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------- ...

证券代码：300653 证券简称：正海生物 烟台正海生物科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |--------------------|-------------|-----------------------|---------------| | | | | 编号：2023003 | | | | | | | 投资者关系活动类别 | □新闻发布会 | □业绩说明会 □路演活动 | | □现场参观 □其他 东北证券 方心宇；国泰基金 姜英；源峰基金 耿华；新华基金 赵 参与单位名 称及人员 姓名 东宇；工银瑞信 丁洋；民生加银 郝梦娇；星石投资 朱宇希；东吴 基金 吴佳歆；长江养老 叶小桃；淳厚基金 严定安；九泰基金 王 宇鸿；太平基金 赵超；嘉实基金 程佳 时 间 2023 年 5 月 26 日 地 点 公司会议室+腾讯会议 上市公司接 待人员姓名 董事长、总经理宋侃先生，副总经理张东刚先生 投资者关系活动主要内容 本次活动主要采用解答提问的方式进行，主要内容如下： 1、公司活性生物骨产品的进展情况如何？ 答：公司的活性生物骨产品正在做相关的转产验证工作 ...

证券代码：300653 证券简称：正海生物 烟台正海生物科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |--------------------|-------------|-----------------------|---------------| | | | | 编号：2023002 | | | | | | | 投资者关系活动类别 | □新闻发布会 | □业绩说明会 □路演活动 | | √现场参观 □其他 深圳市徐星私募 张东伟；杭州哲云私募 丁谢峰；个人投资者 徐方 参与单位名 称及人员 姓名 云、赵连平、姜荣光、刘凡、王居福、邹萍萍、陈建花、胡荣雁； 证券日报 彭春来、赵宁、赵彬彬、王僖等人 时 间 2023 年 5 月 10 日、2023 年 5 月 11 日 地 点 公司会议室 上市公司接 待人员姓名 董事长、总经理宋侃先生 投资者关系活动主要内容 本次活动主要采用解答提问的方式进行，主要内容如下： 1、公司的业绩及分红情况如何？ 答：回顾过去几年公司业绩保持稳定增长。2017 年至 2022 年，营业收入由 1.83 亿元增长至 4.33 亿元， ...

烟台正海生物科技股份有限公司 2023 年第一季度报告 证券代码：300653 证券简称：正海生物 公告编号：2023-031 烟台正海生物科技股份有限公司 2023 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 3.第一季度报告是否经过审计 □是 否 1 烟台正海生物科技股份有限公司 2023 年第一季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 是 □否 追溯调整或重述原因 □会计政策变更 □会计差错更正 □同一控制下企业合并 其他原因 | | 本报告期 | 上年同期 | | 本报告期比上年同期 | | --- | --- | --- | --- | --- | | | | | | 增减（%） | | | | ...

Revenue and Financial Performance - The company's operating revenue for 2022 was ¥433,224,730.58, an increase of 8.26% compared to ¥400,175,251.94 in 2021[28]. - The net profit attributable to shareholders for 2022 was ¥185,436,805.06, reflecting a growth of 10.02% from ¥168,552,584.39 in 2021[28]. - The net profit after deducting non-recurring gains and losses was ¥172,608,159.41, up 7.29% from ¥160,878,004.21 in 2021[28]. - The net cash flow from operating activities increased by 13.06% to ¥187,838,040.27 in 2022 from ¥166,134,014.20 in 2021[28]. - Basic earnings per share rose by 36.17% to ¥1.28 in 2022, compared to ¥0.94 in 2021[28]. - Total assets at the end of 2022 reached ¥986,904,775.50, a 6.24% increase from ¥928,920,991.12 at the end of 2021[28]. - The net assets attributable to shareholders increased by 10.17% to ¥865,107,791.65 at the end of 2022 from ¥785,270,986.59 at the end of 2021[28]. - The company achieved a net profit of 185.44 million yuan in 2022, representing a year-on-year growth of 10.02%[49]. - Total revenue for 2022 reached 433.22 million yuan, an increase of 8.26% compared to the previous year[50]. Product Development and Market Position - The main revenue sources for the company are the oral repair membrane and absorbable dura (spinal) membrane patches, both of which have experienced rapid growth in recent years[5]. - The company is focused on regenerative medicine, aiming to develop innovative products to meet clinical needs[36]. - The company’s R&D efforts are aimed at developing new products, although the process is lengthy and involves significant investment[7]. - The company has successfully registered new products including "self-etching adhesive" and "active biological bone," expanding its product offerings[45]. - The company is currently conducting clinical trials for several key projects, including light-cured composite resin and calcium silicate bioceramic bone repair materials[79]. - The company is in the process of launching new products, including a breast patch for reconstruction and a uterine cavity repair membrane[79]. - The company is actively developing new products and technologies, with a focus on enhancing the efficacy of its active biological bone and skin repair membrane[110]. Risk Management and Challenges - The company emphasizes the importance of enhancing management capabilities and market expansion to mitigate potential risks from external changes[5]. - The company is focused on addressing risks related to product concentration and external environmental changes, which could affect future growth[5]. - Regulatory changes and external environment shifts, including centralized procurement policies, present ongoing challenges for maintaining market competitiveness[105]. - The company faces risks due to a concentrated product portfolio, with a focus on regenerative medicine and ongoing development of new products like active biological bone and second-generation dura membranes[104]. - Product quality is critical, as any issues could adversely affect both health outcomes and the company's operations[106]. Governance and Management - The company has established a governance structure that ensures compliance with relevant laws and regulations, enhancing operational transparency and risk management[113]. - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements[115]. - The company has maintained independence from its controlling shareholder in terms of assets, personnel, finance, and operations, achieving a "five independence" standard[117]. - The company has a strong management team with members holding advanced degrees and extensive experience in the biotechnology and pharmaceutical sectors[126]. - The company has appointed several independent directors with significant experience in finance and management to strengthen its governance[124]. Shareholder Engagement and Profit Distribution - The profit distribution plan approved by the board is a cash dividend of 6.00 RMB per 10 shares (including tax), with no bonus shares issued[7]. - The company aims to distribute at least 20% of the annual distributable profit as cash dividends, increasing to 10% if there are significant investment plans or cash expenditures[145]. - The company has maintained a stable profit distribution policy, with adjustments requiring thorough research and approval from the board and shareholders[150]. - The board of directors will consider shareholder feedback, especially from minority shareholders, when proposing cash dividend plans[148]. - The company distributed a cash dividend of RMB 105.6 million to shareholders, with a distribution of RMB 8.80 per 10 shares[166]. Market Expansion and Sales Strategy - The company has successfully participated in volume-based procurement in six provinces, including Jiangsu and Shandong, without significant pressure on performance, although future expansions of procurement may impact growth[5]. - The company is focusing on expanding its market presence and product applications, particularly in the fields of oral repair and neurosurgery[110]. - The company actively participated in around 750 academic activities to enhance market presence and brand recognition[52]. - The company has over 1,100 distributors nationwide, ensuring a broad marketing network and strong brand recognition in the market[62]. - The company is exploring potential mergers and acquisitions to bolster its market position and expand its product offerings[110]. Quality Management and Compliance - The company has established a comprehensive quality management system, achieving ISO 13485 and ISO 9001 certifications[64]. - The quality management system maintained a 100% pass rate for product inspections, ensuring stable and effective quality management throughout the reporting period[57]. - The company has implemented a supplier evaluation management system, conducting annual assessments to control product quality from the source[171]. - The company has established a monitoring group for adverse events related to product quality, ensuring rapid response and consumer protection[170]. - The internal control system has been strengthened to ensure compliance with laws and regulations, enhancing risk management and operational efficiency[155]. Employee Development and Welfare - The total number of employees at the end of the reporting period is 376, with 163 in production, 105 in sales, 61 in technical roles, 7 in finance, and 40 in administration[140]. - The company has established a comprehensive employee welfare system, providing nearly 20 types of benefits[168]. - The company has conducted training programs to enhance employee skills and support business innovation[168]. - The company emphasizes continuous and stable profit distribution policies, prioritizing cash dividends over stock dividends[144]. Environmental Responsibility - The company has implemented various environmental protection measures, including the installation of pollution control equipment and the use of natural gas boilers[162]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[163]. - Environmental protection measures include the installation of various eco-friendly equipment, ensuring compliance with local environmental regulations[171].